Galen, a member of the Almac Group, has completed a multi-million pound acquisition of POA Pharma, a boutique healthcare company, significantly expanding its global reach and product portfolio in new therapy areas, such as rare metabolic disease.   POA Pharma, based in Sweden, with additional facilities across the Nordic region and North America, represents 16 producers from 10 countries with a portfolio of products and an extensive global network. Galen first signed a distribution agreement w...